309 related articles for article (PubMed ID: 32295606)
1. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
[TBL] [Abstract][Full Text] [Related]
2. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
Gort L; de Olano N; Macías-Vidal J; Coll MA;
Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
4. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
5. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.
Maegawa GH; Stockley T; Tropak M; Banwell B; Blaser S; Kok F; Giugliani R; Mahuran D; Clarke JT
Pediatrics; 2006 Nov; 118(5):e1550-62. PubMed ID: 17015493
[TBL] [Abstract][Full Text] [Related]
6. Plasma G
Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
[TBL] [Abstract][Full Text] [Related]
7. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.
Cordeiro P; Hechtman P; Kaplan F
Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652
[TBL] [Abstract][Full Text] [Related]
8. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
Tsuji D; Akeboshi H; Matsuoka K; Yasuoka H; Miyasaki E; Kasahara Y; Kawashima I; Chiba Y; Jigami Y; Taki T; Sakuraba H; Itoh K
Ann Neurol; 2011 Apr; 69(4):691-701. PubMed ID: 21520232
[TBL] [Abstract][Full Text] [Related]
9. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).
Clarke JT; Mahuran DJ; Sathe S; Kolodny EH; Rigat BA; Raiman JA; Tropak MB
Mol Genet Metab; 2011 Jan; 102(1):6-12. PubMed ID: 20926324
[TBL] [Abstract][Full Text] [Related]
10. The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis.
Mahuran DJ
Biochim Biophys Acta; 1991 Feb; 1096(2):87-94. PubMed ID: 1825792
[No Abstract] [Full Text] [Related]
11. Improvement of motor and behavioral activity in Sandhoff mice transplanted with human CD34+ cells transduced with a HexA/HexB expressing lentiviral vector.
Beegle J; Hendrix K; Maciel H; Nolta JA; Anderson JS
J Gene Med; 2020 Sep; 22(9):e3205. PubMed ID: 32335981
[TBL] [Abstract][Full Text] [Related]
12. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in molecular genetics of GM2 gangliosidosis].
Wakamatsu N
Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
[TBL] [Abstract][Full Text] [Related]
14. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
[TBL] [Abstract][Full Text] [Related]
15. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
[TBL] [Abstract][Full Text] [Related]
16. Biochemical consequences of mutations causing the GM2 gangliosidoses.
Mahuran DJ
Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic journey for patients with late-onset GM2 Gangliosidoses.
Lopshire MC; Tifft C; Burns J; Gould R; Zheng R; Batsu I
Mol Genet Metab Rep; 2023 Dec; 37():101014. PubMed ID: 38053937
[TBL] [Abstract][Full Text] [Related]
18. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
Norflus F; Yamanaka S; Proia RL
DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
